Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kaylee Casper

Nurse Practitioner Auburn, IN Nurse Practitioner

NPI 1770172728 CMS profile 10844358

1061 Smaltz Way, Auburn, IN 46706

Open in the dashboard

General payments

$4,303

201 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kaylee Casper of Auburn, IN is reported in the CMS Open Payments database as having received $4,303 across 201 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $342 15
2024 General $674 37
2023 General $1,433 82
2022 General $1,363 55
2021 General $491 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kaylee Casper
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Kaylee Casper were reported at $342. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Kaylee Casper Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $491 $135 $40–$426 $132
2022 $1,363 $152 $48–$470 $149
2023 $1,433 $166 $54–$529 $160
2024 $674 $173 $55–$556 $164
2025 $342 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,256 69 payments
  2. Lilly USA, LLC $474 18 payments
  3. AstraZeneca Pharmaceuticals LP $312 17 payments
  4. GlaxoSmithKline, LLC. $308 11 payments
  5. Biohaven Pharmaceutical Holding Company Ltd. $217 7 payments
  6. Novo Nordisk Inc $202 11 payments
  7. Amgen Inc. $199 6 payments
  8. Axsome Therapeutics, Inc. $162 5 payments
  9. Pfizer Inc. $160 9 payments
  10. ITI, Inc. $151 4 payments
  11. Other $861 44 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,303 201 payments
Products named General payments · program years 2021–2025
  1. UBRELVY $677 36 payments
  2. VRAYLAR $458 23 payments
  3. MOUNJARO $425 14 payments
  4. FARXIGA $237 13 payments
  5. NURTEC ODT Primary Care $217 7 payments
  6. QULIPTA $209 17 payments
  7. EVENITY $199 6 payments
  8. Auvelity $162 5 payments
  9. NURTEC ODT Pain $160 9 payments
  10. CAPLYTA $151 4 payments
  11. Other $2,068 111 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 67 drugs

Part D claims

1,794

Median for Nurse Practitioner: 389

Drug cost

$176,222

Median for Nurse Practitioner: $21,885

Branded share of claims

20.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 44 $49,855
Trulicity Dulaglutide Brand 19 $25,832
Mounjaro Tirzepatide Brand 23 $24,456
Eliquis Apixaban Brand 21 $19,241
Auvelity Dextromethorphan Hbr/Bupropion Brand 12 $13,540
Trintellix Vortioxetine Hydrobromide Brand 13 $9,434
Toujeo Solostar Insulin Glargine,hum.Rec.Anlog Brand 11 $8,185
Linzess Linaclotide Brand 11 $7,933
Pregabalin Generic 31 $1,696
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 17 $1,634

The 10 drugs with the highest cost, of 67 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$18,993

Of which drugs: $1,098

Medicare patients

94

Average age 72

Services billed

320

48 women, 46 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 48%
Depression 33%
Diabetes 30%
Ischemic heart disease 28%
Chronic kidney disease 18%
COPD 18%
Atrial fibrillation 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 12 13 $1,054

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $111
$111 23 —
VRAYLAR
  • AbbVie, Inc. $90
$90 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $60
$60 — —
UBRELVY
  • AbbVie, Inc. $50
$50 — —
Veozah
  • Astellas Pharma US Inc $40
$40 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

201 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record